Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Study to Investigate the Effect of Bupivacaine Liposomal Injectable Suspension (BLIS) on Opioid Use, Hospital Length of Stay, Discharge Status and Hospitalization Costs in Patients Undergoing Total Hip Arthroplasty (THA) at High Use Hospitals

X
Trial Profile

A Retrospective Study to Investigate the Effect of Bupivacaine Liposomal Injectable Suspension (BLIS) on Opioid Use, Hospital Length of Stay, Discharge Status and Hospitalization Costs in Patients Undergoing Total Hip Arthroplasty (THA) at High Use Hospitals

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2019 Primary endpoint (Home discharge status: BLIS compared to control (in both the Medicare and commercial insurance groups)) has been met, according to results presented in a Pacira BioSciences media release.
    • 12 Jun 2019 Primary endpoint (Hospital length of stay (LOS): BLIS compared to control (in both the Medicare and commercial insurance groups)) has been met, according to results presented in a Pacira BioSciences media release.
    • 12 Jun 2019 According to a Pacira BioSciences media release, new data from this study were published in The Journal of Medical Economics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top